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The pharmacological treatment of depression consists of stages of trial and error, with less than 40% of patients achieving remission
during ﬁrst medication trial. However, in a large, randomized-controlled trial (RCT) in the U.S. (“GUIDED”), signiﬁcant improvements in
response and remission rates were observed in patients who received treatment guided by combinatorial pharmacogenomic testing,
compared to treatment-as-usual (TAU). Here we present results from the Canadian “GAPP-MDD” RCT. This 52-week, 3-arm, multi-center,
participant- and rater-blinded RCT evaluated clinical outcomes among patients with depression whose treatment was guided by
combinatorial pharmacogenomic testing compared to TAU. The primary outcome was symptom improvement (change in 17-item
Hamilton Depression Rating Scale, HAM-D17) at week 8. Secondary outcomes included response (≥50% decrease in HAM-D17) and
remission (HAM-D17 ≤ 7) at week 8. Numerically, patients in the guided-care arm had greater symptom improvement (27.6% versus
22.7%), response (30.3% versus 22.7%), and remission rates (15.7% versus 8.3%) compared to TAU, although these differences were not
statistically signiﬁcant. Given that the GAPP-MDD trial was ultimately underpowered to detect statistically signiﬁcant differences in patient
outcomes, it was assessed in parallel with the larger GUIDED RCT. We observed that relative improvements in response and remission
rates were consistent between the GAPP-MDD (33.0% response, 89.0% remission) and GUIDED (31.0% response, 51.0% remission) trials.
Together with GUIDED, the results from the GAPP-MDD trial indicate that combinatorial pharmacogenomic testing can be an effective
tool to help guide depression treatment in the context of the Canadian healthcare setting (ClinicalTrials.gov NCT02466477).
Translational Psychiatry (2022)12:101 ; https://doi.org/10.1038/s41398-022-01847-8

INTRODUCTION
The pharmacological treatment of depression consists of stages
of trial-and-error prescribing, with less than 40% of patients
achieving remission during their ﬁrst medication trial and

declining remission rates with each subsequent trial [1]. To help
improve this state of affairs, organizations such as the Clinical
Pharmacogenetics Implementation Consortium (CPIC), the Dutch
Pharmacogenetics Working Group (KNMP), the United States (U.S.)
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Food and Drug Administration (FDA), and the International Society
of Psychiatric Genetics (ISPG) provide recommendations and
guidance on the use of pharmacogenetic information for several
common psychotropic medications [2–6]. A growing body of
evidence supports the use of pharmacogenomic testing to help
guide the pharmacological treatment of depression and improve
patients’ likelihood of achieving remission [7–9].
Combinatorial pharmacogenomic testing is distinct from other
testing approaches, such as single- and multi-gene genetic
testing, as it uses a weighted algorithmic assessment of multiple
pharmacokinetic and pharmacodynamic genes to predict genedrug interactions [10, 11]. The clinical utility of a combinatorial
pharmacogenomic test has been assessed through both openlabel and blinded clinical trials [10, 12–15]. This includes an
evaluation of the clinical utility of combinatorial pharmacogenomic testing to guide the treatment of depression in the largest
randomized controlled trial (RCT; N = 1167) of pharmacogenomic
testing in psychiatry, performed in the U.S. from 2014 to 2017 [14].
Among patients with major depressive disorder (MDD) who failed
at least one previous medication trial, the Genomics Used to
Improve DEpression Decisions (GUIDED) trial demonstrated that
combinatorial pharmacogenomic testing was associated with
signiﬁcant relative increases in both response (31%) and remission
(51%) rates, compared to treatment-as-usual (TAU) [14]. Furthermore, meta-analyses have demonstrated that combinatorial
pharmacogenomic testing is associated with a 49% relative
increase in remission rates among patients with depression who
have failed at least one previous medication trial when compared
with patients who receive standard care [9].
The presence of universal healthcare in Canada, compared to
the U.S., makes access to healthcare more equitable across socioeconomic strata [16]. As the nature and cost of healthcare differs
between the U.S. and Canada, several studies have evaluated the
economic and clinical beneﬁt of combinatorial pharmacogenomic
testing in the Canadian system. The economic utility of
combinatorial pharmacogenomic-guided treatment of depression
in Canada has been demonstrated through studies of pharmacy
claims and cost-effectiveness modeling [17, 18]. These studies
report reduced healthcare costs in patients who receive treatment
guided by combinatorial pharmacogenomic testing, compared to
TAU. In terms of clinical utility, IMPACT (Individualized Medicine:
Pharmacogenetics Assessment and Clinical Treatment), a large,
single-arm, naturalistic study, demonstrated improvement in
depression symptoms, response, and remission rates following
combinatorial pharmacogenomic testing among Canadian
patients with moderate to severe depression [15]. This singlearm study provides preliminary evidence of the clinical utility of
combinatorial pharmacogenomic testing in Canada.
Although the existing evidence supports the effectiveness of
combinatorial pharmacogenomic testing in a Canadian population, a direct evaluation in a patient- and rater-blinded RCT has not
yet been reported. Here we present results from the Canadian
Genomic Applications Partnership Program-Major Depressive
Disorder (GAPP-MDD) RCT on the use of combinatorial pharmacogenomic testing to guide depression treatment. The GAPP-MDD
trial evaluated clinical outcomes when treatment was guided by a
combinatorial pharmacogenomic test (guided-care) compared to
TAU among Canadian patients with MDD who had at least one
previous failed medication trial.
MATERIALS AND METHODS
Trial design
The GAPP-MDD trial (ClinicalTrials.gov: NCT02466477) was a 52-week, threearm, multi-center, patient- and rater-blinded, randomized, controlled trial
evaluating clinical outcomes among patients whose treatment was guided by
combinatorial pharmacogenomic testing compared to TAU. Patients were
enrolled at screening between June 2015 and June 2018. Patient assessments

were conducted at weeks 0 (baseline), 4, 8, 12, 24, 36, and 52. The analyses
presented here focus on outcomes at Week 8. The 17-item Hamilton
Depression Rating Scale (HAM-D17) was the primary assessment and was
administered by blinded central rater. The self-rated 16-item Quick Inventory
of Depression Symptomology (QIDS-SR16), a secondary assessment, was also
administered at each visit. Additional description of the trial design has been
reported in the Supplementary Materials.
The trial protocol was approved by Advarra research ethics board,
Clinical Trials Ontario, Hamilton Integrated Research Ethics Board (HiREB),
and IRB Schulman, and was performed in accordance with the principles of
the Declaration of Helsinki. All patients provided informed consent after
receiving a complete description of the study.

Interventions: combinatorial pharmacogenomic testing
GeneSight® Psychotropic combinatorial pharmacogenomic testing was
performed by Assurex Health Ltd. (Toronto, ON) on all patients enrolled in
the GAPP-MDD trial, using previously described methods [19]. Standard
testing (GEN) included select polymorphisms measured within 8 genes
(CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, HTR2A, and SLC6A4;
U.S. patent no. 8,401,801 and U.S. patent no. 8,688,385). Seven additional
polymorphisms within 6 genes shown to have genetic variation associated
with antipsychotic-induced weight gain (MC4R, CNR1, NPY, GCG, HCRTR2,
NDUFS1) [20–25] were measured for a subset of patients receiving
“enhanced GeneSight” (EGEN) testing (U.S. patent no. 10,662,475). Genomic
DNA was isolated from buccal samples, and the relevant genomic regions
were ampliﬁed by polymerase chain reaction (PCR). Speciﬁc mutations for
CYP2B6 (A785G, G516T) and SLC6A4 were detected by gel electrophoresis of
PCR products. Analysis of CNR1, CYP1A2, CYP2C19, CYP2C9, CYP3A4, GCG,
HCRTR2, HTR2A, MC4R, NDUFS1, and NPY was completed by using a custom
xTAG® assay (Luminex Molecular Diagnostics). Analysis of CYP2D6 was
completed using xTAG® kits (Luminex Molecular Diagnostics). The following
genetic variants may be detected in the assay: CNR1 rs806378;
CYP1A2 −3860G > A, −2467T > delT, −739T > G, −729C > T, −163C > A,
2116 G > A, 2499 A > T, 3497 G > A, 3533 G > A, 5090 C > T, 5347 C > T;
CYP2B6 *1, *4, *6, *9; CYP2C19 *1, *2, *3, *4, *6, *8, *17; CYP2C9 *1, *2, *3,
*5, *6; CYP2D6 *1, *2, *2 A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17,
*41, gene duplication; CYP3A4 *1, *13, *15 A, *22; GCG rs13429709; HCRTR2
rs3134701, rs4142972; HTR2A −1438G > A; MC4R rs489693; NDUFS1 rs6435326;
NPY rs16147; SLC6A4 L, S (Supplementary Table 1).
An algorithm weighed the combined inﬂuence of each individual
genotype on patient response to each individual medication [10]. Based
on this weighted and combined phenotype, 33 Health Canada-approved
psychotropic medications (Supplementary Table 2) were categorized based
on three levels of gene-drug interaction: “use as directed” (no gene-drug
interactions), “use with caution” (moderate gene-drug interactions; i.e.,
medications may be effective with dose modiﬁcation), and “use with
increased caution and with more frequent monitoring” (severe gene-drug
interactions that may signiﬁcantly impact drug safety and/or efﬁcacy).

Randomization and blinding
Pharmacogenomic testing was performed for all patients between the
screening and baseline visits. Patients were randomized 1:1:1 to one of three
treatment arms, including two intervention arms and a TAU arm. The ﬁrst
intervention arm included patients for whom providers received the
standard combinatorial pharmacogenomic test report to guide treatment
(GEN arm). The second intervention arm included patients for whom
providers received an enhanced combinatorial pharmacogenomic test report
to guide treatment (EGEN arm; report included 6 additional genes shown to
have genetic variation associated with antipsychotic-induced weight gain).
Patients in the control arm (TAU) also received active treatment for their
MDD; however, treatment did not include provision of the combinatorial
pharmacogenomic test results and recommendations.
Both the patients and raters were blinded to the study arm. The treating
clinician had knowledge of the intervention arm because the combinatorial pharmacogenomic report was available to them for patients in the GEN
and EGEN arms to guide their treatment approach. In the TAU arm,
patients and clinicians were blinded to the combinatorial pharmacogenomic test results until after completion of their week 36 visit.

Participants
The detailed inclusion and exclusion criteria are described in the
Supplementary Methods. Brieﬂy, patients were included in the study if they
were ≥18 years old, diagnosed with MDD (according to DSM-IV criteria,
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QIDS-C16 score ≥11 at screening, and QIDS-SR16 score ≥11 at screening and
baseline), and had inadequate response to at least one psychotropic
medication included on the combinatorial pharmacogenomic report within
the current depressive episode. Patients were excluded if they had
signiﬁcant suicidal risk, severe co-occurring psychiatric or cognitive
disorders, and/or unstable or signiﬁcant medical conditions. Patients were
recruited from both psychiatric care and primary care settings.

pharmacodynamics of a medication. Incongruent medications were
classiﬁed as those that were subject to signiﬁcant gene-drug interactions
for the given patient. Patients were classiﬁed as taking congruent
medications if none of their prescribed medications were subject to
signiﬁcant gene-drug interactions (i.e., none of their medications were
classiﬁed in the “use with increased caution and with more frequent
monitoring” bin on the pharmacogenomic report).

Outcomes

Data analysis. All analyses were performed according to a pre-speciﬁed
statistical analysis plan, available on clinicaltrials.gov as of April 23, 2019
(NCT02466477). Patient demographics and clinical characteristics were
assessed using descriptive statistics for the PP and ITT cohorts. A 3-sample
test for the equality of proportions was used to assess differences between
the 3 treatment arms after randomization for categorical measures and
one-way ANOVA was used for continuous measures. A 2-sample test for
the equality of proportions was used to compare the number of patients
who previously failed three or more medications between treatment arms.
Analyses were performed for patients who completed the study through
week 8. The severity of depression was categorized according to HAM-D17
scores: 0–7, normal; 8–13, mild depression; 14–18, moderate depression;
19–22, severe depression; ≥23, very severe depression.
A Mixed Model for Repeated Measures (MMRM) including treatment
group, week, baseline HAM-D17 score, treatment group-by-week interaction, and baseline HAM-D17-by-week interaction was used for both change
and percentage change from baseline in HAM-D17. A generalized linear
mixed model including treatment group, week, baseline HAM-D17 score,
treatment group-by-week interaction, and baseline HAM-D17-by-week
interaction was used for response and remission in HAM-D17. A Chi-Square
test was used for medication congruence analyses. Two-sided P values ≤
0.05 were considered statistically signiﬁcant. Analyses were performed
using SAS software (Version 9.4) and JMP 15 (SAS Institute).

The following outcomes were pre-speciﬁed in the Statistical Analysis Plan,
available on clinicaltrials.gov as of April 23, 2019 (NCT02466477). The
primary outcome was symptom improvement, deﬁned as the mean percent
change in HAM-D17 score from baseline to week 8, compared between the
GEN and TAU arms in the per-protocol (PP) cohort. Symptom improvement
was also compared between GEN and TAU in the intent-to-treat (ITT) cohort.
Additionally, the mean absolute change in HAM-D17 score from baseline to
week 8 was compared between GEN and TAU arms in both cohorts.
Symptom improvement from baseline to week 8 and response and
remission rates at week 8 were compared between the EGEN and GEN
arms. If no statistically signiﬁcant difference was observed between the
EGEN and GEN arms for any of these outcomes, it was pre-speciﬁed that
the two arms would be combined into the single “guided-care” arm for all
of the subsequent analyses.
The following secondary patient outcomes were compared between the
study arms at week 8 in both the PP and ITT cohorts: (1) Response at week
8, deﬁned as ≥ 50% decrease in HAM-D17 from baseline, and (2) Remission
at week 8, deﬁned as having a score of ≤ 7 for HAM-D17. Symptom
improvement, response, and remission, deﬁned using the HAM-D17 scale,
were also evaluated at week 24. The proportion of patients taking only
congruent medications at baseline and week 4 and 8 follow-up were
assessed in the study arms in both the PP and ITT cohorts.
The number needed to treat (NNT) for response and remission was
deﬁned as the number of subjects required to receive combinatorial
pharmacogenomic testing in order for one more subject in the GEN or
EGEN treatment arms to achieve the clinical outcome (i.e., response or
remission) above that observed in the TAU group.

Statistical analysis
Analysis cohorts. Patient outcomes were assessed in the following prespeciﬁed cohorts: PP and ITT. As speciﬁed in the study protocol, QIDS-C16
was not conducted at baseline and therefore not included as a
requirement for either cohort. The ITT cohort included patients who met
eligibility criteria, with the exception of the baseline QIDS-SR16 < 11
requirement; patients with a QIDS-SR16 < 11 were included in analyses as
randomization occurred before baseline. As the intention of the trial was to
assess the clinical utility of the combinatorial pharmacogenomic test in
patients with moderate or worse depression, the PP cohort excluded
patients who did not meet this criterion. Therefore, the PP cohort included
the subset of patients who met eligibility criteria and additionally excluded
patients who had baseline scores <14 on the HAM-D17 to exclude patients
with mild depression. Patients were also excluded if they had clinically
relevant protocol violations, as described in CONSORT Diagrams (Supplementary Figs 1, 2), or if their clinician did not view the electronic
combinatorial pharmacogenomic report prior to the baseline visit (GEN
and EGEN arms only, for the latter).
The ﬁnal ITT and PP cohorts included 371 patients, and 276 patients,
respectively. Patient recruitment was terminated prior to achieving the target
enrollment sample size (N = 570), which was based on effect sizes of an early
open-label study of pharmacogenomic testing, as described in the
Supplementary Methods. The early termination of this trial was based on
analyses of results from the large GUIDED trial, which was similar in design to
the GAPP-MDD trial, and had the same primary outcome. Primary results for
the GUIDED trial were reported in May 2018, when the GAPP-MDD trial was
still actively enrolling. Using the effect size observed in the GUIDED trial,
power was reassessed, and the target sample size for the GAPP-MDD study
was found to be powered at less than 25% probability to detect a statistically
signiﬁcant difference between arms. To achieve 90% power, approximately
N = 4000 patients would be required, which was not feasible for this trial.
Medication congruence with combinatorial pharmacogenomic testing.
Medication congruence was based on whether a medication was subject
to gene-drug interactions as determined by the combinatorial pharmacogenomic test results for a given patient [11]. Gene-drug interaction refers
to genetic variation that is predicted to impact the pharmacokinetics or
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Evaluation of GAPP-MDD and GUIDED. As the design of the Canadian
GAPP-MDD trial resembled that of the large U.S. GUIDED trial, [14] these
studies were assessed in parallel. In order to evaluate the similarities in
patient outcomes between the two trials, endpoints from each study (i.e.,
outcomes at week 8) are presented here in a side-by-side table when similar
data were available (Supplementary Table 3). As described previously, part of
the rationale for the current study was to evaluate the clinical utility of
combinatorial pharmacogenomic testing to guide depression treatment in
the context of the Canadian healthcare system. Therefore, including the U.S.
GUIDED results provides context to the Canadian GAPP-MDD results.
Meta-analysis. A meta-analysis was performed to compare the ﬁndings
from the GAPP-MDD trial with those from previous similarly designed RCTs.
Clinical outcomes were compared between baseline and week 8 for the
GAPP-MDD and GUIDED [14] trials, and week 10 for the Winner et al. trial [12].
Symptom improvement from baseline was measured by the percentage
change in HAM-D17 from baseline. Mean percentage of symptom
improvement at week 8 or week 10 comparing the combinatorial
pharmacogenomic-guided care arm to TAU (treatment as usual) and
standard error of the mean from each study were used for the metaanalysis. For response and remission, the odds ratio (OR) comparing the
combinatorial pharmacogenomic-guided care arm to TAU at week 8 or week
10 with standard error for each study was used for analyses. The pooled
mean effect of symptom improvement and pooled odds ratios of response
and remission for the three studies were calculated using a ﬁxed effects
model. The ﬁxed effects model was used as the study designs were the same
and the studies all estimate the same treatment effect. Heterogeneity in
effect sizes across studies were tested using the Q-statistic and its magnitude
was measured with the I2 statistic. Meta-analyses were run using the meta
package in R version 4.0.2. The NNT for each study was calculated using the
following equation: 1/AAR, where AAR (Absolute Attributable Risk) was
the absolute value of (CER – EER); CER (Control Event Rate) was the event rate
(i.e., number of patients achieving response or remission) in the TAU arm and
EER (Experimental Event Rate) was the event rate in the combinatorial
pharmacogenomic test-guided arm. The NNT for all studies was calculated
using the combined CER and EER across the three studies.

RESULTS
Cohort description
Study enrollment and follow-up for patients in the PP and ITT cohorts
are presented in CONSORT diagrams (Supplementary Figs 1, 2).

A.K. Tiwari et al.

4
Table 1.

Demographic characteristics in the GAPP-MDD clinical trial at baseline by treatment in the per-protocol cohort.

Demographics

Treatment

Total (N = 276)

p-value

TAU (N = 93)

GEN (N = 90)

E-GEN (N = 93)

18 to 34

35 (37.6)

42 (46.7)

32 (34.4)

109 (39.5)

0.21

35 to 49

27 (29.0)

21 (23.3)

32 (34.4)

80 (29.0)

0.26

50 to 64

25 (26.9)

20 (22.2)

25 (26.9)

70 (25.4)

0.71

65 and over

6 (6.5)

7 (7.8)

4 (4.3)

17 (6.2)

0.61

Mean (SD)

42.3 (14.2)

40.3 (15.3)

40.7 (12.9)

41.1 (14.1)

0.62

Min, Max

20.0, 78.0

19.0, 76.0

18.0, 69.0

18.0, 78.0

–

Age group, n (%)

Age

Gender, n (%)
Female

59 (63.4)

59 (65.6)

60 (64.5)

178 (64.5)

0.96

Male

34 (36.6)

31 (34.4)

33 (35.5)

98 (35.5)

0.96

Asian

7 (7.5)

10 (11.1)

7 (7.5)

24 (8.7)

0.61

Black

1 (1.1)

3 (3.3)

4 (4.3)

8 (2.9)

0.40

Caucasian

83 (89.2)

72 (80.0)

77 (82.8)

232 (84.1)

0.21

Latin American

2 (2.2)

2 (2.2)

1 (1.1)

5 (1.8)

0.81

Other

0

3 (3.3)

4 (4.3)

7 (2.5)

0.15

Ethnicity, n (%)a

Depression category, n (%)
Moderate (HAM-D17 14–18)

28 (30.1)

26 (28.9)

30 (32.3)

84 (30.4)

0.88

Severe (HAM-D17 19–22)

25 (26.9)

24 (26.7)

27 (29.0)

76 (27.5)

0.92

Very severe (HAM-D17 > 22)

40 (43.0)

40 (44.4)

36 (38.7)

116 (42.0)

0.71

Generalized anxiety disorder

35 (37.6)

45 (50.0)

38 (40.9)

119 (43.1)

0.23

Panic disorder

8 (8.6)

15 (16.7)

15 (16.1)

38 (13.8)

0.21

Post-traumatic stress disorder

7 (7.5)

7 (7.8)

8 (8.6)

22 (8.0)

0.96

Mean (SD)

21.4 (4.5)

21.3 (4.7)

21.5 (4.8)

21.4 (4.7)

0.99

Min, Max

14.0, 36.0

14.0, 36.0

14.0, 33.0

14.0, 36.0

–

1

28

14

20

62

0.0598

2

20

23

15

58

0.29

3

12

8

14

34

0.44

4

9

17

8

34

0.07

5

8

7

10

25

0.77

6+

13

20

24

57

0.12

Missingb

3

1

2

6

0.62

Mean (SD)

3.0 (2.2)

3.7 (2.2)

4.0 (3.1)

3.6 (2.6)

0.0388

Min, Max

1.0, 9.0

1.0, 8.0

1.0, 21.0

1.0, 21.0

–

Psychiatric comorbidities, n (%)

HAM-D17

Number of failed psych meds, n

a

Expanded ethnicity groupings are presented in Supplementary Tables 10–12.
b
Patient who reported failing ≥1 prior medication trial, but did not report speciﬁc number of prior failed trials.

A total of 570 patients were planned for enrollment, with 190 in
each of the TAU, GEN, EGEN arms in accordance with the protocol.
After early termination of enrollment due to subsequent
determination of lack of power, the ﬁnal ITT cohort consisted of
371 patients who completed the baseline visit (N = 118 TAU, N =
125 GEN, N = 128 EGEN; Supplementary Fig. 1). In the PP cohort,
an additional 95 patients were excluded after randomization as
they had a baseline HAMD-17 score <14 or had other protocol
violations. Therefore, the ﬁnal per-protocol cohort consisted of
276 patients (N = 93 TAU, N = 90 GEN, N = 93 EGEN; Supplementary Fig. 2).

Although the primary analyses focus on the PP cohort, the
results from the ITT analyses are also shown here for reference.
The baseline demographic characteristics of the PP cohort are
presented in Table 1. The same information for the ITT cohort can
be found in Supplementary Table 4. In the PP cohort, the majority
of patients were female (64.5%), 18–64 years of age (93.9%; mean
age 41 years), and self-reported as “Caucasian” (84.1%). The mean
HAM-D17 score was 21.4, with 30.4% of patients classiﬁed as
having moderate, 27.5% severe, and 42% very severe depression.
Generalized anxiety disorder was the most common psychiatric
comorbidity (43.1%). The mean number of lifetime previously
Translational Psychiatry (2022)12:101
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Table 2.

Week 8 symptom improvement in the GEN and TAU treatment arms, according to HAM-D17.
Symptom improvement
Mean percentage change

Mean change

Estimate,% (SE)

Difference

p-value

GEN (N = 65)

24.41 (3.85)

1.82

0.738

TAU (N = 69)

22.60 (3.80)

a

Estimate (SE)b

Difference

p-value

5.23 (0.74)

0.13

0.901

0.672

0.414

Per Protocol
5.10 (0.73)

Intent-to-Treat
GEN (N = 106)

22.42 (3.42)

TAU (N = 97)

17.80 (3.55)

4.61

0.350

4.70 (0.57)
4.03 (0.59)

a

Mean percent change in HAM-D17 score from baseline to week 8.
Mean absolute change in HAM-D17 score from baseline to week 8.

b

failed psychiatric medications was 3.6. The rate of three or more
failed medications in the TAU arm was 46.7% (42/90) compared to
60% in GEN + EGEN arm (108/180; p = 0.051). A total of 196
patients in the PP cohort had HAM-D17 scores available at the
week 8 endpoint (N = 69 TAU, N = 65 GEN, N = 62 EGEN), and 149
patients had HAM-D17 scores available through the blinded week
24 endpoint (N = 55 TAU, N = 48 GEN, N = 46 EGEN).
Clinical outcomes
There was no signiﬁcant difference in the primary endpoint,
percent decrease in HAM-D17 score, between the GEN and TAU
arms at week 8 in the PP cohort (GEN 24.4 vs TAU 22.6, p = 0.738),
nor was there a difference in the mean absolute decrease in HAMD17 score between GEN and TAU (GEN 5.2 vs TAU 5.1, p = 0.901;
Table 2). Similar results were found in the ITT cohort (Table 2).
When comparing the GEN and EGEN arms at week 8 in the PP
cohort, there was no signiﬁcant difference in HAM-D17 endpoints (symptom improvement, p = 0.244; response, p = 0.332;
remission, p = 0.834; Supplementary Table 5). Furthermore, due
to the similarity between the combinatorial pharmacogenomic
algorithms used in the GEN and EGEN arms, there was no
difference at week 8 in medication binning on the pharmacogenomic report according to the two algorithms (i.e., medications categorized as “use as directed”, “use with caution”, or “use
with increased caution and with more frequent monitoring”). At
week 24, only one patient was taking a medication that changed
bins in the GEN and EGEN algorithms, but this did not impact
their congruence categorization. Based on the above, and as
prespeciﬁed in the Statistical Analysis Plan, the GEN and EGEN
arms were combined for the remainder of the study and referred
to as the guided-care arm.
The key outcomes comparing the guided-care and TAU arms at
week 8 in the GAPP-MDD study are provided in Fig. 1 and
Supplementary Table 3. To help interpret these results and
provide additional clinical context, the corresponding data from
the prior GUIDED study are also presented. As shown, in the PP
cohort of the current GAPP-MDD study, compared to TAU,
patients in the guided-care arm had greater HAM-D17-measured
symptom improvement (27.6% versus 22.7%; p = 0.274), higher
response rate (30.3% versus 22.7%; p = 0.262), and higher
remission rate (15.7% versus 8.3%; p = 0.131), although comparisons did not reach statistical signiﬁcance. Nonetheless, these
statistically non-signiﬁcant values in the GAPP-MDD study are in
the direction of improvement, with relative improvements of 22%
in symptoms, 33% in response rates, and 89% in remission rates
among patients in the guided-arm, compared to TAU. Findings in
the ITT cohort at week 8 were similar.
The durability of clinical outcomes was also compared between the
guided-care and TAU arms at week 24 (Supplementary Tables 6, 7).
Translational Psychiatry (2022)12:101

In the PP cohort, patients in the guided-care arm experienced an
improvement in HAM-D17-measured symptom improvement,
response, and remission rates compared to patients in the TAU
arm, although no differences reached statistical signiﬁcance. In the
ITT cohort, patients in the guided-care arm continued to
experience greater HAM-D17-measured symptom improvement,
response, and remission through week 24 compared to patients in
the TAU arm, although these improvements did not reach
statistical signiﬁcance.
Decision impact regarding medication congruence
The proportion of patients taking congruent medications at baseline
and week 8 was compared between the guided-care and TAU arms
in the PP cohort (Fig. 2; Supplementary Table 8). Congruent
prescribing increased over the course of the study in the guidedcare arm but not in the TAU arm. In the guided-care arm, 83.4% of
patients were taking genetically congruent medications at baseline,
which increased to 91.1% at week 8. Conversely, in the TAU arm,
81.1% of patients were taking genetically congruent medications at
baseline, and 82.1% were taking congruent medications at week 8
(p = 0.070 for the guided-care arm compared to TAU at week 8).
Similar results were observed within the ITT cohort (Fig. 2;
Supplementary Table 8).
Clinical outcomes in the GAPP-MDD and GUIDED RCTs
As the design of the GAPP-MDD trial resembled that of the U.S.
GUIDED trial, clinical outcomes and congruency were presented
for the two studies in parallel. The improvement in clinical
outcomes observed in the PP cohort of the GAPP-MDD trial was
similar to what was observed in the GUIDED trial (Supplementary
Table 9). In fact, improvement in HAM-D17-measured symptom
improvement, response, and remission at week 8 in the guidedcare arm compared to TAU was numerically greater in the GAPPMDD trial, compared to GUIDED (Fig. 1; Supplementary Table 3). In
addition, the increase in medication congruence within the
guided-care arms was consistent between studies. Findings within
the ITT cohort for GAPP-MDD and GUIDED were also similar (Fig. 1;
Supplementary Table 3).
Meta-analysis
The primary end point of the three studies was symptom
improvement, measured as percent change from baseline
HAMD-17 score to week 8 (for GAPP-MDD and GUIDED trials)
or 10 (for Winner et al. 2013). The effect size of symptom
improvement was consistent across the three studies (Q = 0.74;
p = 0.69; I2 = 0). The ﬁxed effects model suggests that symptom
improvement was signiﬁcantly better when combinatorial
pharmacogenomic test results were available to the physician,
with HAM-D17 scores decreasing an additional 3.33% (95% CI:
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A.
GAPP-MDD Trial (current data)

GUIDED Trial (previously published data)
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5
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Decrease in HAM-D17 (%)
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5
0

p=0.103
p=0.005
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21.9% 19.8% 25.1% 26.1%
(N=97) (N=677) (N=211) (N=621)

TAU
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Study Arm

5
0

9.7% 11.4% 16.4% 16.8%
(N=97) (N=677) (N=211) (N=621)

TAU
Guided-Care
Study Arm

Fig. 1 HAM-D17 clinical outcomes at 8 weeks by treatment arm in the GAPP-MDD clinical trial and the previous GUIDED trial [14]. A Perprotocol (PP) cohort. GAPP-MDD trial: Guided care arm N = 127, TAU arm N = 69; GUIDED trial: Guided care arm N = 560, TAU arm N = 607. B Intentto-treat (ITT) cohort. GAPP-MDD trial: Guided care arm N = 211, TAU arm N = 97); GUIDED trial: Guided care arm N = 621, TAU arm N = 677.

0.17–6.49; p = 0.039) from baseline to week 8 or 10 for guidedcare versus TAU (Fig. 3A).
Overall response based on HAM-D17 was also evaluated for the
three studies, deﬁned as at least a 50% reduction in HAM-D17
score from baseline to week 8 or 10. The effect size of response
was consistent across the three studies (Q = 0.41; p = 0.82; I2 = 0).
The pooled odds ratio from the ﬁxed effects model suggests the
guided-care arm had a 44% relative improvement in response rate
compared with the TAU arm (OR = 1.44, 95% CI: 1.12–1.85; p =
0.004; Fig. 3B). The NNT (i.e., number of patients needed in the
GEN and EGEN arms for one more patient to achieve clinical
outcomes) for the response was 13.16 for GAPP-MDD, 16.39 for
GUIDED, and 6.58 for Pine Rest. The combined NNT for response
across the three studies was 14.47.
All three studies also evaluated remission, deﬁned as HAMD17 ≤ 7 at week 8 or 10. The effect size of remission was
consistent across the three studies (Q = 0.524; p = 0.77; I2 = 0).

The pooled odds ratio from the ﬁxed effects model suggests that
the guided-care arm achieved a 69% relative improvement in
remission compared to TAU (OR = 1.69, 95% CI: 1.22–2.34; p =
0.001; Fig. 3C). The NNT for remission was 13.51 for GAPP-MDD,
19.23 for GUIDED, and 8.55 for Pine Rest. The NNT for remission
across all three studies combined was 17.62.
DISCUSSION
In both the U.S. and Canada, pharmacotherapy is a ﬁrst-line
treatment option for patients suffering from MDD [26, 27].
However, approved medications can differ across countries, along
with healthcare pathways and costs associated with treatment.
Therefore, it is important to evaluate the clinical utility of
combinatorial pharmacogenomic testing and conﬁrm the U.S.
ﬁndings in other populations, including Canadian patients with
MDD. The GAPP-MDD trial presented clinical outcomes among
Translational Psychiatry (2022)12:101
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100%

GAPP-MDD Trial (current data)

Guided-Care
Patients Taking Genetically
Congruent Medications (%)

95%

TAU

GUIDED Trial (previously published data)
Guided-Care
TAU

90%

85%

80%

75%
70%
0

4

8

Week

Fig. 2 Medication congruency by week in the Per-Protocol cohort
of the GAPP-MDD clinical trial and the previous GUIDED trial [14].
The proportion of patients taking genetically congruent medications from the GAPP-MDD and GUIDED trials are shown in blue and
orange, respectively. Squares represent Guided-Care treatment
arms, and circles represent TAU treatment arms.

MDD patients in Canada whose treatment was guided by
combinatorial pharmacogenomic testing compared to TAU.
Although this trial was underpowered to detect statistically
signiﬁcant differences, numeric improvements in depression
symptoms, response rate, and remission rates were observed
among patients in the guided-care arm (i.e., who received
treatment guided by combinatorial pharmacogenomic testing),
compared to TAU. Combinatorial pharmacogenomic-guided
treatment also resulted in positive treatment decision impact for
prescribing clinicians, where the proportion of patients taking
congruent medications increased to over 90% in the guided-care
arm, with no change in the TAU arm.
As the intention of the GAPP-MDD trial was to evaluate the
utility of the combinatorial pharmacogenomic test in a Canadian
population, this trial was assessed in conjunction with a trial
conducted in a U.S. population (GUIDED trial). In the GAPP-MDD
trial, relative improvements observed in depression symptoms,
response, and remission rates in the guided-care arm were
consistent with those reported in GUIDED. The GUIDED trial was a
larger RCT (N = 1167) and was, therefore, better powered to
achieve statistical signiﬁcance. The results from the GAPP-MDD
trial were consistent with signiﬁcant improvements in response
and remissions rates from the GUIDED trial, even though the
GAPP-MDD trial, itself, was statistically underpowered. Notably, of
the outcomes assessed, we observed the most improvement in
remission rates in both studies (51% in GUIDED, statistically
signiﬁcant; 89% in GAPP-MDD, not statistically signiﬁcant). This is
particularly relevant, as remission, the resolution of depression
symptoms, is the most challenging endpoint to achieve when
treating MDD, and the Canadian Network for Mood and Anxiety
Treatments (CANMAT) identiﬁes symptom remission as the
primary target of the acute treatment of MDD [28]. The ﬁndings
from the GAPP-MDD trial, although not statistically signiﬁcant, are
broadly consistent with other studies in the ﬁeld. Given that trialand-error is the most common strategy for antidepressant
prescribing, even small gains in response can be clinically
meaningful. The meta-analysis contributes to the growing body
of evidence on the clinical usefulness of combinatorial pharmacogenomics testing [10, 12–15, 29, 30].
Changes in clinicians’ prescribing of genetically congruent
medications in GAPP-MDD paralleled that of the GUIDED trial.
Both studies reported a similar increase in clinicians prescribing
congruent medications for patients in the guided-care arm, but
not TAU arm. This demonstrates consistency in the decision
Translational Psychiatry (2022)12:101

impact of combinatorial pharmacogenomic testing when clinicians have the test available to guide treatment decisions. The
high baseline medication congruence in both studies may have
resulted from the trial and error involved in selecting an average
of 3.6 prior medications per patient; this may have further resulted
in more patients on congruent medications. Still, the number of
patients in the guided-care arm who were prescribed noncongruent (i.e., genetically discordant) medications decreased by
50% during the study, whereas no decrease occurred in patients in
the TAU arm.
A notable difference between the GAPP-MDD and GUIDED RCTs
is the ethnicity composition of the patient cohorts. In the PP
cohort of both studies, the majority of patients reported
“Caucasian” as their ethnicity (GAPP-MDD 84.1%, GUIDED
73.5%). Additionally, the second most common self-reported
ethnicity was different between the two studies (“Asian” in the
GAPP-MDD cohort, 8.7%; “Black” in the GUIDED cohort, 14.5%).
There was also a considerable difference in the proportion of
patients who identiﬁed as “Latin American” (GAPP-MDD 1.8%,
GUIDED 7.9%) between studies. These distributions of patient
ethnicities are largely consistent with those observed on a
population level within the respective country in which each
study was run [31, 32]. Despite differences in self-reported
ethnicity between the GAPP-MDD and GUIDED trials, we observed
similar improvements in patient outcomes in both cohorts.
One important component of both the GAPP-MDD and GUIDED
RCTs is the assessment of outcomes in both the PP and ITT
cohorts. In the GAPP-MDD trial, the demographic characteristics of
the PP and ITT cohorts were comparable, with the exception that
patients with no or mild depression were included in the ITT
cohort. Additionally, all patients in the PP cohort had moderate,
severe, or very severe depression, whereas 13% of the patients in
the ITT cohort had no or mild depression, as determined by
baseline HAM-D17 scores of 0–7 and 8–13, respectively. Despite
some demographic differences between each of the two cohorts,
results were similar, with improved clinical outcomes in the
guided-care arm, compared to TAU.
There were several limitations to the current study. The
statistical power and design of the GAPP-MDD was determined
using effect size estimates for symptom improvement (mean
percent change in HAM-D17 score from baseline to week 8) from
an earlier open-label clinical trial of combinatorial pharmacogenomic testing [13]. However, as the GAPP-MDD trial was in
progress, it became apparent upon release of data from the much
larger GUIDED RCT, that the current trial was underpowered based
on the GUIDED RCT effect size for symptom improvement.
However, we include the GUIDED trial results in this report to
provide additional clinical context and relevance. Additional
limitations of the GAPP-MDD trial include the following: the
majority of the cohort were “Caucasian” (as determined by selfreport); lack of assessment of adherence; the impact of
polypharmacy on outcomes was not evaluated; and the sample
size in the PP and the ITT populations differed due to exclusion of
patients with no or mild depression from the PP analyses
(although results were similar in both cohorts). In addition,
positive expectations are known to inﬂuence treatment response.
Since the clinicians were not blinded to study arm, positive
expectations might have subtle inﬂuence on the observations
made in this study. A potential strength of the GAPP-MDD study is
that this patient population received care under the universal
Canadian healthcare system; therefore, socioeconomic biases
related to accessibility and affordability of care may have been
reduced (although this may have varied by speciﬁc study site).
In summary, we observed similar improvement in clinical
outcomes following combinatorial pharmacogenomic testing in
a Canadian population of patients with MDD who failed to
respond to at least one previous medication trial as was seen in
the large U.S. GUIDED trial. The similar effect sizes in response and

A.K. Tiwari et al.

8

A.

Symptom Improvement
Study
Pine Rest
GUIDED
GAPP-MDD

Mean Difference

TE seTE

10.10 [ −8.01; 28.21] 3.0%
2.84 [ −0.61; 6.29] 84.0%
4.92 [ −3.88; 13.72] 12.9%

10.10 9.2400
2.84 1.7600
4.92 4.4900

3.33
3.33

Fixed effect model
Random effects model
Prediction interval
Heterogeneity: I 2 = 0%, W 2 = 0, p = 0.69

−20 −10

B.

0

10

[ 0.17; 6.49] 100.0%
[ 0.17; 6.49]
−−
[−17.17; 23.83]

3.0%
84.0%
12.9%
−−
100.0%

20

Response
Study
Pine Rest
GUIDED
GAPP-MDD

TE

Odds Ratio

seTE

OR

Weight
Weight
95%−CI (fixed) (random)

2.14 [0.60; 7.64]
1.40 [1.07; 1.85]
1.48 [0.74; 2.93]

0.76 0.6500
0.34 0.1400
0.39 0.3500

Fixed effect model
Random effects model
Prediction interval

Heterogeneity: I 2 = 0%, W 2 = 0, p = 0.82

0.2

C.

Weight Weight
95%−CI (fixed) (random)

MD

0.5

1

2

3.8%
82.9%
13.3%

3.8%
82.9%
13.3%

1.44 [1.12; 1.85] 100.0%
1.44 [1.12; 1.85]
−−
[0.28; 7.26]

−−
100.0%

5

Remission
Study
Pine Rest
GUIDED
GAPP-MDD

TE

seTE

OR

Odds Ratio

Weight
Weight
95%−CI (fixed) (random)

2.75 [0.48; 15.71]
1.62 [1.14; 2.30]
2.05 [0.80; 5.26]

1.01 0.8900
0.48 0.1800
0.72 0.4800

Fixed effect model
Random effects model
Prediction interval
Heterogeneity: I 2 = 0%, W 2 = 0, p = 0.77
0.1

0.5 1

2

3.5%
84.6%
11.9%

3.5%
84.6%
11.9%

1.69 [1.22; 2.34] 100.0%
1.69 [1.22; 2.34]
−−
[0.21; 13.89]

−−
100.0%

10

Fig. 3 Meta-analysis of randomized-controlled trials evaluating combinatorial pharmacogenomic testing. A Meta-analysis of symptom
improvement. B Meta-analysis of response. C Meta-analysis of remission.

remission between the two studies indicate that the differences
observed in the GAPP-MDD trial may represent true differences
between arms that did not reach statistical signiﬁcance due to
cohort size. Therefore, results from the GAPP-MDD trial, conducted
in the context of the Canadian universal healthcare setting,
together with evidence from the GUIDED trial, indicate that
combinatorial pharmacogenomic testing is an additional tool
available to clinicians that provides clinically useful information to
help guide the treatment of depression.
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